Hsing-Wu Chen

Hsing-Wu Chen

Auto-generated profile, based on publicly available information

Hsing-Wu Chen

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
HCHsing-Wu Chen
Hsing-Wu Chen
YKYao-Wen Kuo
Yao-Wen Kuo
CCChung-Yu Chen
Chung-Yu Chen
CCChin-Hao Chang
Chin-Hao Chang
SWSu-Mei Wang
Su-Mei Wang
CYChong-Jen Yu
Chong-Jen Yu
Reports of tuberculosis (TB) during anticancer treatment with immune checkpoint inhibitors (ICIs) are increasing. However, it is not clear whether the use of ICIs is a significant risk factor for TB, including reactivation or latent TB infection (LTBI). To determine the risk of TB reactivation in patients with lung cancer who use ICIs or tyrosine kinase inhibitors (TKIs), we conducted a retrospective study using a hospital-based cancer registry. In addition, we monitored patients with cancer using ICI or TKI in a multicenter prospective study to check the incidence of LTBI. In the retrospective study, several demographic factors were imbalanced between the ICI and TKI groups: the ICI group was younger, had more males, exhibited more squamous cell carcinoma in histology rather than adenocarcinoma, had fewer EGFR mutations, and received more chemotherapy. Propensity score matching was used to control for confounding factors, and we found that the incidence of TB was higher among patients with lung cancer who received ICIs than among those who received TKIs (2298 vs 412 per 100 000 person-years, P = .0165). Through multivariable analysis, group (ICI vs TKI) was the independent risk factor for TB development (adjusted hazard ratio (aHR): 6.29, 95% CI, 1.23-32.09, P = .0269). In the prospective cohort, which included 72 patients receiving ICIs and 50 receiving TKIs, we found that the incidence of positive seroconversion of LTBI by interferon gamma release assay (IGRA) was significantly higher in patients receiving ICIs (18% vs 0%, aHR: 9.88, P = 0.035) under multivariable Cox regression. The use of ICIs may be linked to a higher likelihood of TB reactivation and LTBI than individuals solely receiving TKIs as anticancer therapy. Consequently, the implementation of a screening program for TB reactivation and LTBI among patients undergoing ICI treatment could prove advantageous by enabling early detection and prompt treatment of the infection.

1 January 2024 in Journal of Cancer Research and Practice
Verified
Journal Article
Open access
SWShu-Cheng Wu
Shu-Cheng Wu
HCHsing-Wu Chen
Hsing-Wu Chen
Inflammatory myofibroblastic tumors (IMTs) are soft-tissue neoplasms with rare metastatic potential. Approximately half of IMTs are positive for an anaplastic lymphoma kinase (ALK) gene rearrangement which causes aberrant expression. Early phase clinical trials have demonstrated the efficacy of ALK inhibitors in the treatment of IMTs. However, there is no definite conclusion on which ALK inhibitor performs best, and data regarding subsequent therapy after first-line ALK inhibitor failure are scarce. Here, we report a case of ALK+ metastatic IMT that demonstrated a dramatic response to first-line alectinib but resulted in rapidly acquired resistance. Repeated biopsy and next-generation sequencing (NGS) showed ALK:c.3604G>A; p.(Gly1202Arg), which is a common mechanism of drug resistance in ALK fusion-positive non-small cell lung cancer. We also report subsequent treatment choices and responses in this patient and perform a literature review regarding similar cases as this rare tumor.

23 March 2024 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
CCChen Chen
Chen Chen
HCHsing-Wu Chen
Hsing-Wu Chen
WLWei-Hsin Lin
Wei-Hsin Lin
PHPei-Ming Huang
Pei-Ming Huang
MLMong-Wei Lin
Mong-Wei Lin
RHRuey-Long Hong
Ruey-Long Hong
In patients with advanced soft tissue sarcoma (STS), surgery had been reported to be associated with superior overall survival (OS). Chemotherapy details for such patients were less reported, and whether multimodal treatment with surgery and chemotherapy provides extra survival benefit remains unclear. We retrospectively reviewed patients with newly diagnosed advanced STS treated at National Taiwan University Hospital from January 1, 2011, to December 31, 2017. OS was calculated from the day of diagnosis of advanced STS to the day of death or last follow-up. Baseline patient characteristics and details regarding surgery and chemotherapy were recorded. A total of 545 patients were diagnosed with STS from 2011 to 2017, of which 226 patients had advanced STS. The median age was 54.7 years, and 54% of patients were women. Approximately 38% of patients with advanced STS underwent surgery and exhibited a trend of longer OS compared with who did not (median = 18.6 vs. 11.9 months, p = 0.083). In the chemotherapy subgroup, the benefit of surgery was more prominent (median = 21.9 vs. 16.5 months, p = 0.037). Patients who received chemotherapy prior to surgery exhibited numerically longer OS than those who underwent surgery first (median = 33.9 vs. 18.3 months, p = 0.155). After adjusting other clinical factors, chemotherapy remained an independent factor associated with favourable OS. Surgery may be more beneficial for the patients who receive chemotherapy. Our results support evaluation of sequential multimodal treatments strategy including surgery and chemotherapy in patients with advanced STS.


26 March 2026 in Journal of Cancer Research and Practice
Verified
Journal Article
Open access
TLTzu-Jung Lin
Tzu-Jung Lin
HCHsing-Wu Chen
Hsing-Wu Chen
Colorectal cancer (CRC) with the BRAF V600E mutation is an aggressive subtype often resistant to conventional chemotherapy. While B-Raf proto-oncogene (BRAF) / Epidermal growth factor receptor (EGFR) inhibitor combinations are now standard for metastatic BRAF V600E CRC, these BRAF inhibitors can cause various adverse effects. Among these adverse effects, pancreatitis is a rare but serious complication that is often under-recognized due to current trials having limited durations and populations. We report the case of a 50-year-old female with metastatic BRAF V600E-mutant colon cancer who achieved an exceptional and durable complete response over 3 years with off-label dabrafenib and trametinib plus cetuximab. Notably, she developed acute necrotizing pancreatitis after more than 3 years of treatment, a significantly longer latency than previously reported, and experienced recurrence upon rechallenge. A literature review confirmed that pancreatitis is a rare complication across all Food and Drug Administration-approved BRAF inhibitors, with varying onset times. This case highlights the potential for late-onset, severe pancreatitis with prolonged BRAF inhibitor use. Given the increasing use of BRAF inhibitors, particularly in CRC, routine monitoring and further mechanistic research are required.